Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2007
05/24/2007WO2005011617A3 Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
05/24/2007WO2004087071A3 Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection
05/24/2007WO2004034973A3 Method of treating snoring and other obstructive breathing disorders
05/24/2007US20070117992 Crystalline citalopram diol intermediate alkali
05/24/2007US20070117978 Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
05/24/2007US20070117870 Enantiomers of N-Desmethyl venlafaxine
05/24/2007US20070117869 Methods for treating coginitive impairment and improving cognition
05/24/2007US20070117867 Kit comprising three independent compositions and methods for building muscle, increasing strength, increasing muscle size, increasing muscle performance and reducing muscle fatigue
05/24/2007US20070117866 Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
05/24/2007US20070117864 Composition for preventing and treating hepatoma
05/24/2007US20070117863 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
05/24/2007US20070117862 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
05/24/2007US20070117861 Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic-amp specific phosphodiesterase inhibitors
05/24/2007US20070117860 Bicyclic indolinesulphonamide derivatives
05/24/2007US20070117859 Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC
05/24/2007US20070117858 Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
05/24/2007US20070117857 Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators
05/24/2007US20070117856 Indazole derivatives
05/24/2007US20070117855 Phenyl-sulfamates as aromatase inhibitors
05/24/2007US20070117853 (+)-3-acetyl-6-chloro-2-[2-(3-(N-(2-hydroxyethyl)-N-isopropylamino)propoxy)-5-methoxyphenyl]benzothiazoline; kappa -opioid receptor agonist
05/24/2007US20070117851 Liquid pharmaceutical compositions of nimodipine
05/24/2007US20070117850 substituted or unsubstituted 2-pyridyl moiety and a pyrozole ring substituted at 4 position with pyridine ring; inhibits the TGF-beta signaling pathway; anticancer, antifibrotic, antitumor, and antiproliferative agents
05/24/2007US20070117849 Alfavbeta3 and alfavbet6 integrin antagonists as antifibrotic agents
05/24/2007US20070117848 e.g. 2-Carboxy-3-benzyloxy-6-methyl-pyran-4(1H)-one; matrix metalloproteinase inhibitors, histone deacetylase inhibitors, or anthrax lethal factor inhibitors; cell growth and division, bone growth, wound healing, embryogenesis, angiogenesis; cardiovascular disease, stroke, arthritis, tumor metastasis
05/24/2007US20070117847 N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists
05/24/2007US20070117846 Processes for producing 1-benzyl-4-[(5,6-dimethoxy-1indanon)-2-yl]methylpiperidine and hydrochloride thereof
05/24/2007US20070117844 5-HTP combination therapy
05/24/2007US20070117843 Quinoline inhibitors of cGMP phosphodiesterase
05/24/2007US20070117842 Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same
05/24/2007US20070117841 Adjusting dosage in response to the comparison of pretreatment levels of stress-activated protein kinase activity to posttreatment levels in treating fibrotic disorder, carcinoma, sarcoma, leukemia, lymphoma, viral infection, inflammatory disorder and tumor necrosis factor-mediated disorder
05/24/2007US20070117840 Receptor antagonist
05/24/2007US20070117839 Two cyclic cinnamide compound
05/24/2007US20070117838 Quinine dosage forms and methods of use thereof
05/24/2007US20070117837 Process for the preparation of amorphous form of a platelet aggregation inhibitor drug
05/24/2007US20070117836 Napthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
05/24/2007US20070117835 Methods and compositions for treating Huntington's disease
05/24/2007US20070117834 Methods and compositions for treating Huntington's disease
05/24/2007US20070117833 Pharmaceutical compositions
05/24/2007US20070117832 Novel compound, corresponding compositons, preparation and/or treatment methods
05/24/2007US20070117831 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
05/24/2007US20070117830 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
05/24/2007US20070117829 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
05/24/2007US20070117828 Pharmaceutical compositions
05/24/2007US20070117827 Compositions for affecting weight loss
05/24/2007US20070117826 Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
05/24/2007US20070117825 Use of amide derivative of ge 2270 factor a3 for the treatment of acne
05/24/2007US20070117824 Spirocyclic compounds
05/24/2007US20070117823 N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof
05/24/2007US20070117822 Novel antimalarial baylis-hillman adducts and a process for the preparation thereof
05/24/2007US20070117821 4-Amino-2-(4-methanesulfonyl-phenylamino)-pyrimidin-5-yl]-(2,3-difluoro-6-methoxy-phenyl)-methanethione, and4-[4-Amino-5-(2,3-difluoro-6-methoxy-thiobenzoyl)-pyrimidin-2-ylamino]-benzenesulfonamide;inhibit cyclin-dependent kinases; antiproliferative and anticarcinogenic agent
05/24/2007US20070117820 1-([3-Chloro-5-trifluoromethylpyridinyl-2-yl]piperidin-4-yl)-3-(1-methyl-isoquinolin--5-yl)-urea hydrochloride; capsaicin receptor antagonist; calcium level blocker; lower fluorescence; neuropathic, postrheumatoid, osteoarthritic, back, cancer pain, neuralgia, migraine, neuropathies, diabetic neuropathy
05/24/2007US20070117819 Methods of suppression of rage gene expression and rage triggered inflammatory genes by selected age-inhibitors
05/24/2007US20070117818 Pyrimidinone compounds useful as kinase inhibitors
05/24/2007US20070117817 Pyrimidine derivatives for treatment of hyperproliferative disorders
05/24/2007US20070117816 Kinase inhibitors
05/24/2007US20070117815 Method of treating cancers with SAHA and pemetrexed
05/24/2007US20070117812 3,5-Difluoro-2-pyridinecarboxamidine; intermediate for preparing dihydropyrimidines for the treatment and prophylaxis of hepatitis B
05/24/2007US20070117811 N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands
05/24/2007US20070117810 Reduction with sodium borohydride; lower content of chloroketone and impurity in final product
05/24/2007US20070117809 Combination therapy for the treatment of cancer
05/24/2007US20070117808 Substituted Cycloalkylpyrrolones As Allosteric Modulators Of Glucokinase
05/24/2007US20070117807 Potassium channel modulators; cardiovascular disorders; antiarrhythmia agents; synthesis
05/24/2007US20070117806 Neutrophilia inhibitor
05/24/2007US20070117805 Modulators and steroid receptors for treatment of diabetes, inflammatory diseases using prodrugs; arthritis, asthma, rhinitis and immunomodulation
05/24/2007US20070117804 Imidazopyrazines as protein kinase inhibitors
05/24/2007US20070117803 Cyclohexyl-1,4-diamine compounds
05/24/2007US20070117802 Met kinase inhibitors
05/24/2007US20070117801 Indane derivatives as modulator of ion channels
05/24/2007US20070117800 Pyrimidinyl-thiophene kinase modulators
05/24/2007US20070117799 Oxabispidine compounds useful in the treatment of cardiac arrhythmias
05/24/2007US20070117798 Morpholine type cinnamide compound
05/24/2007US20070117797 Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
05/24/2007US20070117796 Carbamate compounds as 5-HT4 receptor agonists
05/24/2007US20070117795 Methods and compositions of novel triazine compounds
05/24/2007US20070117794 Methods of treatment using oxytocin receptor agonists
05/24/2007US20070117793 Compounds Which Inhibit Beta-Secretase Activity and Methods of Use
05/24/2007US20070117792 Pharmaceutical compositions for suppressing b-amyloid production
05/24/2007US20070117791 Bicyclic compounds
05/24/2007US20070117790 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
05/24/2007US20070117789 Method of treatment
05/24/2007US20070117788 Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases
05/24/2007US20070117787 N-[(3R,5S)-1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid; in combination with a statin, lowering cholesterol-level and lowering triglyceride-level
05/24/2007US20070117786 Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives
05/24/2007US20070117785 Substituted pyrazoles and methods of treatment with substituted pyrazoles
05/24/2007US20070117784 Treatment of hyperproliferative diseases with anthraquinones
05/24/2007US20070117783 Aqueous suspensions of ciclesonide for nebulisation
05/24/2007US20070117782 Inhibitors of epoxide hydrolases for the treatment of inflammation
05/24/2007US20070117781 Pharmaceutical formulation with improved stability
05/24/2007US20070117780 Process to Prepare Eplerenone
05/24/2007US20070117779 Use of lipid conjugates in the treatment of disease
05/24/2007US20070117778 Beta glycolipids as immuno-modulators
05/24/2007US20070117777 beta-1,3/1,6 glucan having a lactic acid as a substituent, produced from Aureobasidium pullulans; reduce an activity of osteoclast cell and concurrently activate osteoblast cell facilitating production of bone
05/24/2007US20070117776 Low Dose Therapy Of DNA Methylation Inhibitors
05/24/2007US20070117775 Compositions and Methods For Treating Inflammatory Disorders
05/24/2007US20070117773 Telomerase-inhibiting ENA oligonucleotide
05/24/2007US20070117770 Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof
05/24/2007US20070117765 Nicotinoyl riboside compositions and methods of use
05/24/2007US20070117764 Compositions comprising macrolide t-cell immunomodulators or immunosuppressants in combination with antibacterials
05/24/2007US20070117763 Compositions and methods for treatment and prevention of metabolic syndrome and its associated conditions with combinations of flavonoids, liminoids and tocotrienols
05/24/2007US20070117762 In particular, use of propionyl-L-carnitine in combination with one or more known useful drugs for preparing medicine for treatment of erectile dysfunction in patients suffering from diabetes mellitus, wherein patients do not respond to treatment with other useful drugs